The Price Institute of Surgical Research, University of Louisville School of Medicine, 511 S. Floyd Street, Louisville, KY 40202, USA.
J Am Coll Surg. 2010 Jun;210(6):966-74. doi: 10.1016/j.jamcollsurg.2010.02.001. Epub 2010 Apr 28.
Early clinical trials investigating the role of tightly controlled glucose levels showed marked benefit in survival of critically ill patients. However, a recent meta-analysis and large randomized controlled trial have failed to reproduce the benefit, showing instead substantially increased risk of dangerous hypoglycemia. We sought to investigate the effects of varying glucose concentrations on previously tested, prognostically significant, innate immune parameters, to define any potential effects of glucose at the cellular level.
After formal approval and informed consent, venous blood samples were collected from young healthy volunteers. Up to 11 corresponding (same-subject) samples were incubated at 100, 350, or 600 mg/dL glucose concentrations and analyzed to determine human leukocyte antigen-DR surface receptor expression, cytokine release, phagocytic capacity, and formation of reactive oxygen species. Data are presented as mean +/- SEM.
After incubation, the change in human leukocyte antigen-DR mean channel fluorescence from resting baseline values in lipopolysaccharide-stimulated monocytes was not significantly different between 100, 350, and 600 mg/dL (1,749 +/- 110; 1,748 +/- 120; and 1,725 +/- 96, respectively; p = 0.89). Tumor necrosis factor-alpha concentrations were significantly lower for samples incubated at higher glucose concentrations (179 +/- 50 pg/mL, 125 +/- 30 pg/mL, and 107 +/- 29 pg/mL; p < 0.05). The phagocytic capacity of the innate immune system was marginally enhanced by glucose. However, the formation of reactive oxygen species was markedly impaired by rising glucose (55% to 66% impairment; p < 0.05).
Increasing glucose concentrations exert considerable opposing effects on several well-established innate immunologic processes. The opposing findings might contribute to recent clinical controversies. Physician judgment and experience are essential to imminent treatment of critically ill and perioperative surgical patients.
早期的临床试验研究了严格控制血糖水平对危重症患者生存的影响,结果显示出明显的益处。然而,最近的一项荟萃分析和大型随机对照试验未能重现这一益处,反而显示出危险低血糖的风险显著增加。我们试图研究不同葡萄糖浓度对先前测试的、具有预后意义的固有免疫参数的影响,以确定葡萄糖在细胞水平上的任何潜在影响。
在正式批准和知情同意后,从年轻健康志愿者采集静脉血样本。将多达 11 个相应的(同一受试者)样本在 100、350 或 600mg/dL 葡萄糖浓度下孵育,并进行分析以确定人类白细胞抗原-DR 表面受体表达、细胞因子释放、吞噬能力和活性氧的形成。数据以平均值 +/- SEM 表示。
孵育后,脂多糖刺激的单核细胞中人白细胞抗原-DR 平均通道荧光从静息基线值的变化在 100、350 和 600mg/dL 之间没有显著差异(分别为 1749 +/- 110;1748 +/- 120;和 1725 +/- 96;p = 0.89)。在较高葡萄糖浓度下孵育的样本中,肿瘤坏死因子-α浓度显著降低(分别为 179 +/- 50pg/mL、125 +/- 30pg/mL 和 107 +/- 29pg/mL;p < 0.05)。葡萄糖略微增强了固有免疫系统的吞噬能力。然而,活性氧的形成受到葡萄糖的显著抑制(抑制率为 55%至 66%;p < 0.05)。
升高的葡萄糖浓度对几种已确立的固有免疫过程产生了相当大的相反影响。这些相互矛盾的发现可能导致了最近的临床争议。在对危重症和围手术期患者进行即时治疗时,医生的判断和经验至关重要。